E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute kidney injury postoperatively in connection with surgery for congenital heart disease |
|
E.1.1.1 | Medical condition in easily understood language |
Acute kidney injury after operation for inborn heart diseases in infants and young children (1-12 months) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of this study is to assess the efficacy of Levosimendan to reduce the postoperative acute kidney injury in pediatric patients undergoing surgery for congenital heart disease (CHDs) having creatinine as an endpoint marker. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to study the hemodynamic parameters, fluid balance, the level of inflammation and other plasma kidney biomarkers (like cystatin C and NGAL), and markers of neural injury. Other parameters to stuidy will be length of surgery, length of CPB, length of mechanical ventilation postoperatively, length of vasoactive therapy, number of vasoactive medications and total amount of infused vasoactive drugs. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provision of informed consent prior to any study specific procedures 2. Female and male children between 1 and 12 months of age 3. Non-restrictive VSD (corrective surgery) 4. Complete AVSD (biventricular repair) 5. Tetralogy of Fallot |
|
E.4 | Principal exclusion criteria |
1. Unbalanced AVSD 2. Age less than one month and more than one year 3. acute operation that is unscheduled operation during the first 24 hours after presentation to the department for thoracic surgery 4. Pre-existing renal disease 5. Liver impairment or disease 6. Infection 7. Use of nephrotoxic drugs (like ibuprofen, angiotensin-converting-enzyme inhibitors, gentamicin, vancomycin) preoperative or postoperative until first post operative day 8. Allergy to Levosimendan or previous use of it, 9. Severe arrhythmias needing pace-maker treatment prior to the operation 10. Severe cardiac dysfunction needing for treatment with extracorporeal membrane oxygenation (ECMO) prior to the operation 11. Severe uncorrected hypotension where the initiation of anesthesia is postponed for its correction 12. Re-operation |
|
E.5 End points |
E.5.1 | Primary end point(s) |
AKI is usually defined as 50% increase in creatinine within 48 hours. Accordingly, the primary outcome in this study is the creatinine level on the second postoperative day. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
On the second postoperative day |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints are the hemodynamic parameters, fluid balance, the level of inflammation and other plasma kidney biomarkers (like cystatin C and NGAL), and markers of neural injury. Other parameters will also be assessed such as length of surgery, length of CPB, length of mechanical ventilation postoperatively, length of vasoactive therapy, number of vasoactive medications and total amount of infused vasoactive drugs. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After the termination of the study the blood samples will be analyzed . The capacity of the analyzing laboratory will determine the time point in which this end point will be evaluated. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will be terminated when the follow-up of the last patient included is completed |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |